Biocon reports Q2 FY25 net loss at Rs. 16 Cr
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
The inspection concluded with the issuance of Form 483 with four observations which are procedural in nature
Reinforces position as first commercially approved contract development and manufacturing organization (CDMO) for ADCs in North America
Strengthening focus in Alzheimer's disease and neuroscience pipeline
Lupin's R&D teams are working on products with a near-zero global warming potential propellant
Our China operations continue under the leadership of the current General Manager of AstraZeneca China
The INTerpath-009 clinical trial demonstrates continued expansion of the INTerpath clinical program
These initiatives signify a substantial boost to healthcare infrastructure across India, aligned with the Prime Minister’s mission of ensuring quality healthcare services nationwide
Union Government will provide a health cover of Rs. 5 lakh to any elderly person above 70 years of age
Subscribe To Our Newsletter & Stay Updated